| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $120,453,438 ) (Continued on the next page) |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01CA263986 | Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology Patients | 002 | 3 | NIH | 12/11/2023 | $344,507 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21NS139480 | Deciphering TREM1/2 Function in Primary Brain Cancer Using a New Model of Glioblastoma | 000 | 1 | NIH | 7/24/2024 | $472,124 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK138503 | Integrating signals that control APOL1 gene expression and drive kidney disease | 000 | 11 | NIH | 1/19/2024 | $540,299 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL175060 | Genetic architecture of tissue factor expression | 000 | 1 | NIH | 7/26/2024 | $674,338 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NR021686 | Leveraging SNAP Policies to Improve the Cardiovascular Health of Low-Income Adults in the United States | 000 | 1 | NIH | 7/30/2024 | $644,279 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AG079864 | Brain Vulnerability in Delirium and Alzheimer’s Disease and Related Dementias: Intersection of Polygenic Risk and Inflammation | 001 | 2 | NIH | 5/2/2024 | $81,724 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AG079864 | Brain Vulnerability in Delirium and Alzheimer’s Disease and Related Dementias: Intersection of Polygenic Risk and Inflammation | 000 | 2 | NIH | 11/15/2023 | $735,517 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL157991 | Mapping & quantifying lymphatic drainage of the arm's alternate pathway | 000 | 4 | NIH | 12/14/2023 | $434,000 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA262629 | Personalized Adoptive T-cell Therapy for AML | 001 | 3 | NIH | 4/17/2024 | $36,426 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA262629 | Personalized Adoptive T-cell Therapy for AML | 000 | 3 | NIH | 12/15/2023 | $655,651 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R33DK131915 | Proteomic Biomarkers Prognostic for Diabetic Wound Healing | 000 | 3 | NIH | 8/20/2024 | $576,445 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R25AG088289 | Aging Research and Entrepreneurial Development Immersion | 000 | 1 | NIH | 8/19/2024 | $270,000 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21MH133001 | Identification of Distinct Biotypes in Clinical High Risk for Psychosis State Using Objective Brain-Based Biomarkers | 001 | 2 | NIH | 5/13/2024 | $15,520 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21MH133001 | Identification of Distinct Biotypes in Clinical High Risk for Psychosis State Using Objective Brain-Based Biomarkers | 000 | 2 | NIH | 1/12/2024 | $139,687 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA257672 | Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy | 001 | 2 | NIH | 4/17/2024 | $35,580 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA257672 | Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy | 000 | 2 | NIH | 12/22/2023 | $640,414 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K99DK134853 | Competing effects of AgRP and POMC neurons on cAMP signaling in downstream neurons in vivo | 000 | 2 | NIH | 1/24/2024 | $90,000 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K23DK138320 | Nicotinamide Adenine Dinucleotide (NAD+) Metabolism During Observational and Experimental Heat Stress and the Effect of Niacinamide Among Individuals at Risk for Mesoamerican Nephropathy | 000 | 1 | NIH | 8/2/2024 | $192,984 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NS126282 | Prospective Validation of Neurophysiologic Outcome Prediction in Acute Brain Injury | 001 | 2 | NIH | 4/10/2024 | $52,273 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NS126282 | Prospective Validation of Neurophysiologic Outcome Prediction in Acute Brain Injury | 000 | 2 | NIH | 12/18/2023 | $672,101 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K08HL161259 | Regulation of endothelial cell phosphatidylserine in thrombosis | 000 | 3 | NIH | 12/15/2023 | $165,024 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AG065311 | A Conversation Aid on Mammography Screening to Support Shared Decision Making between Clinicians and Women Aged 75 and Older | 001 | 5 | NIH | 5/13/2024 | $62,031 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AG065311 | A Conversation Aid on Mammography Screening to Support Shared Decision Making between Clinicians and Women Aged 75 and Older | 000 | 5 | NIH | 11/29/2023 | $558,278 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258372 | Role of extracellular matrix proteins and tumor stroma in DNA repair and cancer progression | 001 | 4 | NIH | 4/17/2024 | $20,017 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258372 | Role of extracellular matrix proteins and tumor stroma in DNA repair and cancer progression | 000 | 4 | NIH | 12/20/2023 | $360,281 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA241194 | Targeting microRNAs in the tumor microenvironment with pHLIP conjugated next generation chemically modified PNAs | 001 | 5 | NIH | 4/17/2024 | $19,214 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA241194 | Targeting microRNAs in the tumor microenvironment with pHLIP conjugated next generation chemically modified PNAs | 000 | 5 | NIH | 1/8/2024 | $345,871 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K23AT011043 | Understanding components of mind-body exercise for physical activity engagement in metabolic syndrome | 000 | 4 | NIH | 1/17/2024 | $162,680 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK130929 | Corticosteroids to Reduce Inflammation in Severe Pancreatitis (CRISP) | 001 | 3 | NIH | 5/15/2024 | $22,823 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK130929 | Corticosteroids to Reduce Inflammation in Severe Pancreatitis (CRISP) | 000 | 3 | NIH | 12/12/2023 | $342,342 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258442 | Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma | 001 | 3 | NIH | 4/17/2024 | $21,229 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258442 | Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma | 000 | 3 | NIH | 12/18/2023 | $352,940 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NR019628 | Biochemical profiling to identify cardiometabolic responsiveness to an endurance exercise intervention | 001 | 4 | NIH | 5/2/2024 | $51,256 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NR019628 | Biochemical profiling to identify cardiometabolic responsiveness to an endurance exercise intervention | 000 | 4 | NIH | 12/21/2023 | $461,292 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258776 | Pan-Cancer characterization of 3’UTR somatic mutations controlling tumor immune evasion | 001 | 3 | NIH | 4/17/2024 | $28,465 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258776 | Pan-Cancer characterization of 3’UTR somatic mutations controlling tumor immune evasion | 000 | 3 | NIH | 1/23/2024 | $512,353 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NS122589 | Neuronal Circuit Controlling Sleep-Promoting Ventrolateral Preoptic Neurons | 001 | 3 | NIH | 4/9/2024 | $26,242 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NS122589 | Neuronal Circuit Controlling Sleep-Promoting Ventrolateral Preoptic Neurons | 000 | 3 | NIH | 1/17/2024 | $337,389 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R00AG076739 | Cis proline directed proteotoxicity in the early development and therapy of traumatic brain injury and vascular dementia | 000 | 3 | NIH | 8/20/2024 | $248,895 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL175300 | Leveraging Large Linked Datasets and Novel Analytic Methods to Understand the Long-term Effectiveness and Value of Cardiac Rehabilitation in Understudied Populations | 000 | 1 | NIH | 7/1/2024 | $789,026 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K08DK123400 | Novel signaling pathways in the ciliary inversin compartment | 000 | 5 | NIH | 12/7/2023 | $164,484 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA248031 | Role of newly identified, thyroid-specific LincRNA in BRAFV600E thyroid carcinoma | 001 | 5 | NIH | 4/17/2024 | $20,017 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA248031 | Role of newly identified, thyroid-specific LincRNA in BRAFV600E thyroid carcinoma | 000 | 5 | NIH | 1/12/2024 | $360,281 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K24HL150321 | Using Claims-Based Signatures of Frailty to Support Individualized Treatment of Aortic Valve Stenosis and Coronary Artery Disease | 000 | 5 | NIH | 12/22/2023 | $120,294 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA240257 | Role of KAT5 in lung cancer | 001 | 5 | NIH | 4/17/2024 | $19,957 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA240257 | Role of KAT5 in lung cancer | 000 | 5 | NIH | 1/24/2024 | $359,239 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NS115972 | Cortical-Meningeal Interactions Underlying Migraine Headache | 001 | 4 | NIH | 4/15/2024 | $32,676 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | P50CA101942 | DF/HCC Kidney Cancer SPORE | 002 | 20 | NIH | 7/31/2024 | $2,219,550 |
| | 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK138529 | A liver-specific mitochondrial carrier that controls energy homeostasis | 000 | 1 | NIH | 7/23/2024 | $511,336 |
|
